216 related articles for article (PubMed ID: 31889159)
1. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
Cao D; Zheng Y; Xu H; Ge W; Xu X
Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V
Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731
[TBL] [Abstract][Full Text] [Related]
3. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
4. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
6. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
7. Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer.
Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Gurkan H; Albayrak D; Tastekin E; Uzunoglu S; Cicin I
Med Oncol; 2015 Jan; 32(1):441. PubMed ID: 25502088
[TBL] [Abstract][Full Text] [Related]
8. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
Raouf S; Bertelli G; Ograbek A; Field P; Tran I
Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
[TBL] [Abstract][Full Text] [Related]
9. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ
ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090
[TBL] [Abstract][Full Text] [Related]
11. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.
Li Z; Huang Y; Zhao R; Cui Y; Zhou Y; Wu X
Sci Rep; 2018 Jan; 8(1):510. PubMed ID: 29323221
[TBL] [Abstract][Full Text] [Related]
14. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
15. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
[TBL] [Abstract][Full Text] [Related]
17. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.
Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS
J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.
Ruan WC; Che YP; Ding L; Li HF
Comb Chem High Throughput Screen; 2018; 21(10):718-724. PubMed ID: 30663563
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
Salvatore L; Bria E; Sperduti I; Hinke A; Hegewisch-Becker S; Aparicio T; Le Malicot K; Boige V; Koeberle D; Baertschi D; Dietrich D; Tortora G; Arnold D
Cancer Treat Rev; 2021 Jun; 97():102202. PubMed ID: 33838596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]